Merck Receives Positive EU CHMP Opinion for KEYTRUDA
23 hours ago · News; Business Wire; Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant ...
Merck Gets CHMP Backing of Keytruda in Malignant Pleural …
10 hours ago · News; Global News Select; Merck Gets CHMP Backing of Keytruda in Malignant Pleural Mesothelioma. ... Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved ...
FDA D.I.S.C.O. Burst: Keytruda
1 day ago · Listen to a soundcast of the 9.17.2024 FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Nov 16, 2023 · Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
FDA approves pembrolizumab with chemotherapy for HER2 …
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults...
Moderna, Merck cancer vaccine with Keytruda improved survival …
Jun 3, 2024 · Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda.
Padcev and Keytruda Double Bladder Cancer Survival - NCI
Nov 30, 2023 · UPDATE: On December 15, 2023, FDA approved enfortumab vedotin (Padcev) in combination with pembrolizumab (Keytruda) for people with bladder cancer that has spread to other parts of the body or cannot be removed surgically.
Adjuvant Keytruda Improves Kidney Cancer Survival - NCI
May 21, 2024 · Pembrolizumab (Keytruda) treatment after surgery helped people with clear-cell renal cell carcinoma live longer in a large trial—a first for this cancer.
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA …
Mar 21, 2024 · KEYLYNK-006 is a randomized, open-label, two-phase Phase 3 trial (ClinicalTrials.gov, NCT03976323) evaluating KEYTRUDA in combination with chemotherapy (pemetrexed plus carboplatin or cisplatin...